Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction

Journal of the American Society of Nephrology

Volumn 17, Issue 2, 2006, Pages 433-441

  Suganuma, Eisuke ^a   Zuo, Yiqin ^a   Ayabe, Nobuhiko ^a   Ma, Ji ^a   Babaev, Vladimir R ^a   Linton, MacRae F ^a   Fazio, Sergio ^a   Ichikawa, Iekuni ^a   Fogo, Agnes B ^a   Kon, Valentina ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; CATHEPSIN S; ELASTIN; HYDRALAZINE; LOSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; ELASTOLYSIS; EXTRACELLULAR MATRIX; FEMALE; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY INJURY; MACROPHAGE; MACROPHAGE MIGRATION; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL;

EID: 33645458374     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005080883     Document Type: Article

References (50)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065, 2003
2. Varma R, Garrick R, McClung J, Frishman WH: Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiol Rev 13: 98-107, 2005
3. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659-663, 2004
4. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-562, 2002
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
6. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004
7. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42: 201-208, 2003
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
9. Fogo AB: Mechanisms in nephrosclerosis and hypertension-beyond hemodynamics. J Nephrol 14(Suppl 4): S63-S69, 2001
10. Ichikawa I: Angiotensin receptors: What is new? Am J Kidney Dis 35: 48-49, 2000
11. Kon V, Jabs K: Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 13: 291-297, 2004
12. Meier P, Maillard M, Burnier M: The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord 5: 15-30, 2005
13. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K; SECURE Investigators: Effects of ramipril and of vitamin E on atherosclerosis: Results of the prospective randomized Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 103: 919-925, 2001
14. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041, 2001
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators: Effects of angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 342: 145-153, 2000
16. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471, 1992
17. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB: Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 14: 2466-2474, 2003
18. Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein E knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14: 311-316, 2003
19. Bro S, Moeller F, Andersen CB, Olgaard K, Nielsen LB: Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 15: 1495-1503, 2004
20. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS: Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16: 109-116, 2005
21. Ayabe N, Suganuma E, Babaev VR, Fogo A, Swift L, Linton MF, Fazio S, Ichikawa I, Kon V: Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 24: 2143-2148, 2004
22. Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S, Kon V: Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis 2005 (Epub ahead of print)
23. Fazio S, Major AS, Swift LL, Cleaves LA, Accad M, Linton MF, Farese RV Jr: Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 107: 163-171, 2001
24. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P: Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102: 576-583, 1998
25. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF: Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25: 1647-1653, 2005
26. Cheng TH, Cheng PY, Shih NL, Chen IB, Wang DL, Chen JJ: Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol 42: 1845-1854, 2003
27. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, Richardson B: Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 48: 746-756, 2003
28. Suganuma E, Babaev V, Hunley TE, Linton M, Fazio S, Ichikawa I, Kon V: Decreased elastin degradation stabilizes atherosclerotic lesions and underlies beneficial effects of angiotensin II antagonism (AIIA). J Am Soc Nephrol 16: 14A, 2005
29. Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, Bidouard JP, Janiak P, Schaeffer P, Herbert JM: Angiotensin ATI receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apoprotein E-deficient mice. J Cardiovasc Pharmacol 38: 395-405, 2001
30. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001
31. Buzello M, Haas CS, Hauptmann F, Gross ML, Faulhaber J, Schultze-Mosgau S, Ehmke H, Ritz E, Amann K: No aggravation of renal injury in apolipoprotein E knockout mice (ApoE(-/-)) after subtotal nephrectomy. Nephrol Dial Transplant 19: 566-573, 2004
32. Mulroney SE, Woda C, Johnson M, Pesce C: Gender differences in renal growth and function after uninephrectomy in adult rats. Kidney Int 56: 944-953, 1999
33. Rizvi SA, Naqvi SA, Jawad F, Ahmed E, Asghar A, Zafar MN, Akhtar F: Living kidney donor follow-up in a dedicated clinic. Transplantation 79: 1247-1251, 2005
34. Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB: Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65: 106-115, 2004
35. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21: 115-121, 2001
36. Fathi R, Isbel N, Short L, Haluska B, Johnson D, Marwick TH: The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43: 45-52, 2004
37. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF: Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100: 2552-2561, 1997
38. Linton MF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 27[Suppl 3]: S35-S40, 2003
39. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ: Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 101: 11779-11784, 2004
40. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005
41. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. Kidney Int Suppl 84: S80-S83, 2003
42. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60[Suppl 1]: S13-S21, 2003
43. Brooke BS, Bayes-Genis A, Li DY: New insights into elastin and vascular disease. Trends Cardiovasc Med 13: 176-181, 2003
44. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, Cleutjens KB, Daemen MJ: The dynamic extracellular matrix: Intervention strategies during heart failure and atherosclerosis. J Pathol 200: 516-525, 2003
45. Shah PK: Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 21: 303-314, 2003
46. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24: 1359-1366, 2004
47. Wojakowski W, Gminski J, Siemianowicz K, Goss M, Machalski M: The influence of angiotensin-converting enzyme inhibitors on the aorta elastin metabolism in diet-induced hypercholesterolaemia in rabbits. J Renin Angiotensin Aldosterone Syst 2: 37-42, 2001
48. Liang C, Wu ZG, Ding J, Jiang JF, Huang GZ, Du RZ, Ge JB: Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol Sin 25: 1426-1432, 2004
49. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ: Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 107: 579-585, 2003
50. Katsuda S, Kaji T: Atherosclerosis and extracellular matrix. J Atheroscler Thromb 10: 267-274, 2003